Viking Global Investors invests in the Fred Hutchinson Cancer Research Centre oncology spin-out Adaptive.

The US-based medical device company has raised $11.6m in its series A round, with investors including Pfizer.

The developer of ADHD treatments has now completed a $13.3m series A round supported by Novartis' corporate venturing fund.

The biotechnology company, which is developing treatments for respiratory diseases, has completed a $41m round in which Novo, GlaxoSmithKline, Novartis and Roche all participated as returning investors.

GlycoBac, a University of Wyoming spin-out business, receives a Small Business Innovation Research grant.

Israel and US-based Cheetah Medical has secured $9m series D fundraising led by Fletcher Spaght Ventures and including Robert Bosch Venture Capital and Ascension Health Ventures.

Pharmaceutical company Alkermes is among the backers to benefit from Celgene's investment, which was made at three times the value of Acceleron's IPO in September.

Kaiser Permanente-backed medical device developer Vapotherm has now raised $53m across two equity rounds.

Seven startups have been chosen by the telecommunications company for its accelerator, which is expanding from California to France.

The Kaiser Permanente-backed company, developer of treatments for heart aneurysms, raised the maximum target for its initial public offering from the initial $100m.